Which biotech CEOs are most ready to forget 2015?
News & Analysis: Orexigen Therapeutics
Shares took a nose dive on Monday after an investment firm published a short report on the company.
Some stocks are just plain awful. Here are three that investors shouldn't touch with a 10-foot pole.
It was expected to be Orexigen's greatest selling point, but this miscue turned into a nightmare for the company's weight-control management drug Contrave.
Returns couldn't have been much worse for these drugmakers this year.
Orexigen Therapeutics' stock took another leg down last month. Here's why.
The downgrade from Well Fargo caps off a lackluster year.
Zafgen falls flat on its face, and Orexigen shareholders cheer!
Discounts and a lack of a European partner derail the obesity drugmaker.
Our contributors think that Medicare recipients of all ages should be aware of these Medicare facts.